Gilead's HIV drug Lenacapavir could reduce costs from $40,000 to $40, aiding high-risk groups. UNAIDS and Byanyima urge licensing via the Medicines Patent Pool. Hill's research supports affordability. Awaiting phase 3 results, Gilead aims for low-cost generics and voluntary licensing in low-income nations, partnering with manufacturers in China and India to fight HIV worldwide.
Gilead's HIV drug Lenacapavir could reduce costs from $40,000 to $40, aiding high-risk groups. UNAIDS and Byanyima urge licensing via the Medicines Patent Pool. Hill's research supports affordability. Awaiting phase 3 results, Gilead aims for low-cost generics and voluntary licensing in low-income nations, partnering with manufacturers in China and India to fight HIV worldwide.
टिप्पणियाँ
एक टिप्पणी भेजें